Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Silence Therapeutics plc Director's Dealing 2025

Jan 2, 2025

33536_dirs_2025-01-02_6966b3b3-5f32-4906-8dac-04b3d1aab546.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Silence Therapeutics plc (SLN)
CIK: 0001479615
Period of Report: 2025-01-02

Reporting Person: TOOMAN CRAIG A (N/A)

Holdings (Non-Derivative)

Security Shares Ownership
Ordinary Shares 33486 Direct

Holdings (Derivative)

Security Exercise Price Expiration Underlying Shares Ownership
Employee Share Option (Right to Buy) $7.02 2031-01-06 Ordinary Shares (580000) Direct
Employee Share Option (Right to Buy) $7.87 2032-01-06 Ordinary Shares (264999) Direct
Employee Share Option (Right to Buy) $6.33 2032-02-21 Ordinary Shares (375000) Direct
Employee Share Option (Right to Buy) $3.86 2032-09-16 Ordinary Shares (900000) Direct
Employee Share Option (Right to Buy) $5.13 2033-01-05 Ordinary Shares (2100000) Direct
Employee Share Option (Right to Buy) $3.33 2033-09-14 Ordinary Shares (216960) Direct
Employee Share Option (Right to Buy) $5.90 2034-01-04 Ordinary Shares (650880) Direct

Footnotes

F1: One fourth (1/4th) of the shares subject to the option award vested on January 6, 2022, and one twelfth (1/12th) of the remaining shares subject to the option award vested or shall vest in equal quarterly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.

F2: This option vested or shall vest in equal monthly installments over a four-year period measured from one month following January 6, 2022, subject to the Reporting Person's continuous service as of the applicable vesting date.

F3: This option vested or shall vest in equal monthly installments over a four-year period measured from one month following February 21, 2022, subject to the Reporting Person's continuous service as of the applicable vesting date.

F4: This option vested or shall vest in equal monthly installments over a five-year period measured from one month following September 16, 2022, subject to the Reporting Person's continuous service as of the applicable vesting date.

F5: This option vested or shall vest in equal monthly installments over a four-year period measured from one month following January 5, 2023, subject to the Reporting Person's continuous service as of the applicable vesting date.

F6: One fourth (1/4th) of the shares subject to the option vested on September 14, 2024 and the remaining shares subject to the option vested or shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service with the Issuer on each such vesting date.

F7: One fourth (1/4th) of the shares subject to the option shall vest on January 4, 2025 and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service with the Issuer on each such vesting date.